Logo - International Journal of Pharmaceutical Compounding

Sevelamer Suspension in Children with End-Stage Renal Disease

Author(s):  McElhiney Linda F

Issue:  Jan/Feb 2007 - Pediatric Patients
View All Articles in Issue

Abstract:  Control of hyperphosphatemia is a major clinical challenge in children with end-stage renal disease. The best treatment option is a calcium-based phosphate binder, but there is evidence that this treatment protocol causes long-term complications, including vascular calcifications. Sevelamer hydrochloride has been shown to be effective in reducing serum phosphorus levels and the calcium-phosphorus ion product in children on maintenance dialysis and may be key in preventing soft-tissue and vascular calcifications in such patients. Until the U.S. Food and Drug Administration approves the use of sevelamer hydrochloride in children undergoing dialysis, and a liquid dosage form becomes available, compounding pharmacists will need to prepare this unique compound for these patients.

Related Keywords: CHILDREN, INFANTS, CHRONIC RENAL FAILURE, KIDNEY FAILURE, END-STAGE RENAL DISEASE, ESRD, HYPERPHOSPHATEMIA, FIXED OIL, RENAGEL, DIALYSIS, PHOSPHORUS, PHOSPHATE BINDERS, SEVELAMER HYDROCHLORIDE, ORAL SUSPENSION, LIQUID PREPARATIONS, DOSAGE FORMS, FORMULATI

Related Categories: FORMULATIONS, NUTRITION AND NUTRICEUTICALS, PEDIATRICS, STABILITIES, COMPATIBILITIES, UROLOGY/URINARY TRACT

Purchase this article for download in electronic PDF format from IJPC at for $35 at:
http://www.ijpc.com/Products/ProductAddToCart.cfm?PID=2510

Search the entire IJPC archive by keyword, topic, or issue at:
http://ijpc.com/Products